Advertise
NEWSLETTER
Jupiter Neurosciences doses...
Cerevance reports Solengepr...
AgelessRx introduces GHK-Cu...
ProMIS appoints new chief c...
Shift uses AI virtual cells...
Jupiter Neurosciences doses...
Cerevance reports Solengepr...
AgelessRx introduces GHK-Cu...
ProMIS appoints new chief c...
Shift uses AI virtual cells...
Nir Barzilai

Can we stop diseases by targeting aging first?

Are you in the right industry?

‘Four FDA-approved drugs decrease overall mortality in humans’

David Sinclair resigns as President of the Academy for Health & Lifespan Research

David Sinclair resigns as President of the Academy for Health & Lifespan Research

Sirtuin-focused biotech cements longevity focus with heavyweight appointment

SIRT6-focused biotech cements longevity focus with heavyweight appointment

SIRT6: The protein that talks the talk and walks the walk

Ahead of the Longevity Investors Conference, our longevity hivemind talks biomarkers, translation and the democratisation of regenerative medicine.

We might not know the future… but we can spot its longevity trends and drivers

Longevity pioneers explain why the field needs to expand, encourage participation and focus on translation.

Taking the longevity field one step beyond

Interviews of 2022 accelerating longevity

Interviews of 2022: accelerating longevity

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE

  • $617BN - Annual global revenue by 2045
  • $30BN+ - Invested in under 2 years
  • 3,036 - Therapeutics individually assessed